This company has been acquired
Adverum Biotechnologies (ADVM) Stock Overview
A clinical-stage company, develops gene therapy product candidates to treat ocular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ADVM Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Adverum Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.36 |
| 52 Week High | US$6.07 |
| 52 Week Low | US$1.78 |
| Beta | 0.87 |
| 1 Month Change | 1.87% |
| 3 Month Change | 38.85% |
| 1 Year Change | -26.48% |
| 3 Year Change | -30.94% |
| 5 Year Change | -96.46% |
| Change since IPO | -98.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADVM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.6% | 2.5% | 2.3% |
| 1Y | -26.5% | 30.9% | 25.5% |
Return vs Industry: ADVM underperformed the US Biotechs industry which returned 16.6% over the past year.
Return vs Market: ADVM underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| ADVM volatility | |
|---|---|
| ADVM Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADVM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADVM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 155 | Laurent Fischer | adverum.com |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy.
Adverum Biotechnologies, Inc. Fundamentals Summary
| ADVM fundamental statistics | |
|---|---|
| Market cap | US$96.26m |
| Earnings (TTM) | -US$184.79m |
| Revenue (TTM) | n/a |
Is ADVM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADVM income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$77.12m |
| Gross Profit | -US$77.12m |
| Other Expenses | US$107.67m |
| Earnings | -US$184.79m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ADVM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 21:47 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adverum Biotechnologies, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graig Suvannavejh | Goldman Sachs |
| Biren Amin | Jefferies LLC |
| Mani Foroohar | Leerink Partners LLC |